Immunome Inc (IMNM)

$10.16 +0.24 (2.42%)
Market Cap 896.56M
Revenue (ttm) 9.04M
Net Income (ttm) -292.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,240.71%
Debt to Equity Ratio 0.00
Volume 1,154,900
Avg Vol 893,392
Day's Range N/A - N/A
Shares Out 87.05M
Stochastic %K 58%
Beta 1.93
Analysts Strong Sell
Price Target $24.38

Company Profile

Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug...

Industry: Biotechnology
Sector: Healthcare
Phone: 425 939 7410
Address:
18702 North Creek Parkway, Suite 100, Bothell, United States
FortuneFlicker
FortuneFlicker Aug. 27 at 9:44 AM
$IMNM consolidating in a tight range, could be setting up for a bigger move.
0 · Reply
JarvisFlow
JarvisFlow Aug. 22 at 4:50 PM
Evercore ISI Group has updated their rating for Immunome ( $IMNM ) to Outperform with a price target of 18.
0 · Reply
Fast_Eddie_Felson
Fast_Eddie_Felson Aug. 20 at 4:58 PM
$IMNM wtf do they even do again?
2 · Reply
Jeff9905
Jeff9905 Aug. 14 at 8:07 PM
$IMNM yep. Someone sold off big. Not much confidence in the data if it even ever comes out. Sad.
1 · Reply
StockBraker
StockBraker Aug. 14 at 7:26 PM
$IMNM Hmmmm 🤔
0 · Reply
Virealize340
Virealize340 Aug. 11 at 7:15 PM
$IMNM she need to hold that $7
0 · Reply
JarvisFlow
JarvisFlow Aug. 7 at 9:30 PM
JP Morgan updates rating for Immunome ( $IMNM ) to Overweight, target set at 23 → 22.
0 · Reply
Jeff9905
Jeff9905 Aug. 6 at 9:49 PM
$IMNM that update was a joke. More delays. Sad.
0 · Reply
Jeff9905
Jeff9905 Aug. 5 at 11:23 PM
$IMNM data ever gonna be released? Why the foot dragging. Not good.
1 · Reply
PremarketAddict
PremarketAddict Aug. 4 at 3:04 AM
NEWS UPDATE: $VZ Notice of Intent to Award Sole Source - CELLCO PARTNERSHIP DBA VERIZON WIRELESS Bridge $LPLA LPL Financial Closes Its Acquisition of Commonwealth Financial Network $OPEN Opendoor regains compliance with Nasdaq requirements and cancels special meeting of stockholders [Seeking Alpha] $IMNM Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
0 · Reply
Latest News on IMNM
Immunome: SpringWorks Buyout Informs The Potential Upside Here

Aug 11, 2025, 10:31 PM EDT - 15 days ago

Immunome: SpringWorks Buyout Informs The Potential Upside Here

Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 4:05 PM EDT - 20 days ago

Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 1, 2025, 5:51 PM EDT - 25 days ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome to Present at Upcoming Investor Conferences

May 22, 2025, 8:00 AM EDT - 3 months ago

Immunome to Present at Upcoming Investor Conferences

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:05 PM EDT - 3 months ago

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update

Immunome: Transformed Pipeline Offers Multiple Catalysts

Apr 17, 2025, 6:06 AM EDT - 4 months ago

Immunome: Transformed Pipeline Offers Multiple Catalysts

Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 4, 2025, 8:00 AM EDT - 5 months ago

Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

Immunome Reports Full Year 2024 Financial Results and Provides Business Update

Mar 19, 2025, 4:05 PM EDT - 5 months ago

Immunome Reports Full Year 2024 Financial Results and Provides Business Update

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC

Mar 10, 2025, 7:41 AM EDT - 6 months ago

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC

Immunome to Present at Upcoming March Conferences

Feb 25, 2025, 8:00 AM EST - 6 months ago

Immunome to Present at Upcoming March Conferences

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 31, 2025, 4:01 PM EST - 7 months ago

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Immunome Can Take The Fight To Competitors With Varegacestat

Jan 30, 2025, 10:27 AM EST - 7 months ago

Immunome Can Take The Fight To Competitors With Varegacestat

Immunome Announces Pricing of Upsized Public Offering of Common Stock

Jan 29, 2025, 11:11 PM EST - 7 months ago

Immunome Announces Pricing of Upsized Public Offering of Common Stock

Immunome Announces Proposed Public Offering of Common Stock

Jan 29, 2025, 4:27 PM EST - 7 months ago

Immunome Announces Proposed Public Offering of Common Stock

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 13, 2025, 8:00 AM EST - 8 months ago

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 9 months ago

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 13, 2024, 4:05 PM EST - 10 months ago

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Nov 5, 2024, 8:00 AM EST - 10 months ago

Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Oct 29, 2024, 8:00 AM EDT - 10 months ago

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

Oct 18, 2024, 8:00 AM EDT - 11 months ago

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

Oct 8, 2024, 8:05 AM EDT - 11 months ago

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

Immunome: AL102 And Other Established Protein Targets Could Drive Value

Jun 27, 2024, 2:14 PM EDT - 1 year ago

Immunome: AL102 And Other Established Protein Targets Could Drive Value

Immunome Appoints Phil Tsai as Chief Technical Officer

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Immunome Appoints Phil Tsai as Chief Technical Officer

Immunome Announces Completion of Purchase of Assets from Atreca

May 20, 2024, 8:00 AM EDT - 1 year ago

Immunome Announces Completion of Purchase of Assets from Atreca

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

May 17, 2024, 8:00 AM EDT - 1 year ago

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

May 14, 2024, 8:00 AM EDT - 1 year ago

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

Immunome to Present at 2024 Bank of America Healthcare Conference

May 8, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present at 2024 Bank of America Healthcare Conference

Immunome Appoints Kinney Horn as Chief Business Officer

May 2, 2024, 8:00 AM EDT - 1 year ago

Immunome Appoints Kinney Horn as Chief Business Officer

Immunome Appoints Sandra M. Swain to Board of Directors

Apr 25, 2024, 8:26 AM EDT - 1 year ago

Immunome Appoints Sandra M. Swain to Board of Directors

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

Apr 5, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

Immunome: An Oncology Powerhouse In The Making

Apr 2, 2024, 2:07 PM EDT - 1 year ago

Immunome: An Oncology Powerhouse In The Making

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Mar 28, 2024, 4:02 PM EDT - 1 year ago

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

Arrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies

Mar 18, 2024, 5:44 AM EDT - 1 year ago

Arrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies

Immunome to Participate in the Leerink Partners Global Biopharma Conference

Mar 7, 2024, 8:00 AM EST - 1 year ago

Immunome to Participate in the Leerink Partners Global Biopharma Conference

Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference

Mar 1, 2024, 8:00 AM EST - 1 year ago

Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference

Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

Feb 20, 2024, 8:15 AM EST - 1 year ago

Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

Immunome Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 16, 2024, 4:05 PM EST - 1 year ago

Immunome Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Immunome Announces Pricing of Public Offering of Common Stock

Feb 13, 2024, 10:38 PM EST - 1 year ago

Immunome Announces Pricing of Public Offering of Common Stock

Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

Feb 6, 2024, 8:00 AM EST - 1 year ago

Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 5, 2024, 8:00 AM EST - 1 year ago

Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform

Jan 8, 2024, 7:00 AM EST - 1 year ago

Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform

ZNTL

Immunome Appoints Phil Roberts as Chief Technical Officer

Jan 4, 2024, 8:00 AM EST - 1 year ago

Immunome Appoints Phil Roberts as Chief Technical Officer

Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 8:00 AM EST - 1 year ago

Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Immunome Appoints Carol A. Schafer to Board of Directors

Jan 2, 2024, 8:00 AM EST - 1 year ago

Immunome Appoints Carol A. Schafer to Board of Directors

Immunome to Acquire Antibody-Related Assets and Materials from Atreca

Dec 26, 2023, 8:30 AM EST - 1 year ago

Immunome to Acquire Antibody-Related Assets and Materials from Atreca

FortuneFlicker
FortuneFlicker Aug. 27 at 9:44 AM
$IMNM consolidating in a tight range, could be setting up for a bigger move.
0 · Reply
JarvisFlow
JarvisFlow Aug. 22 at 4:50 PM
Evercore ISI Group has updated their rating for Immunome ( $IMNM ) to Outperform with a price target of 18.
0 · Reply
Fast_Eddie_Felson
Fast_Eddie_Felson Aug. 20 at 4:58 PM
$IMNM wtf do they even do again?
2 · Reply
Jeff9905
Jeff9905 Aug. 14 at 8:07 PM
$IMNM yep. Someone sold off big. Not much confidence in the data if it even ever comes out. Sad.
1 · Reply
StockBraker
StockBraker Aug. 14 at 7:26 PM
$IMNM Hmmmm 🤔
0 · Reply
Virealize340
Virealize340 Aug. 11 at 7:15 PM
$IMNM she need to hold that $7
0 · Reply
JarvisFlow
JarvisFlow Aug. 7 at 9:30 PM
JP Morgan updates rating for Immunome ( $IMNM ) to Overweight, target set at 23 → 22.
0 · Reply
Jeff9905
Jeff9905 Aug. 6 at 9:49 PM
$IMNM that update was a joke. More delays. Sad.
0 · Reply
Jeff9905
Jeff9905 Aug. 5 at 11:23 PM
$IMNM data ever gonna be released? Why the foot dragging. Not good.
1 · Reply
PremarketAddict
PremarketAddict Aug. 4 at 3:04 AM
NEWS UPDATE: $VZ Notice of Intent to Award Sole Source - CELLCO PARTNERSHIP DBA VERIZON WIRELESS Bridge $LPLA LPL Financial Closes Its Acquisition of Commonwealth Financial Network $OPEN Opendoor regains compliance with Nasdaq requirements and cancels special meeting of stockholders [Seeking Alpha] $IMNM Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 29 at 11:13 PM
$IMNM Great piece that accurately captures IMNM's current position. So if you want to refresh your understanding of IMNM or learn about IMNM for the first time, this is essential reading. https://beyondspx.com/article/immunome-pipeline-catalysts-and-technological-edge-drive-oncology-ambition-nasdaq-imnm
2 · Reply
Jeff9905
Jeff9905 Jul. 22 at 8:17 PM
$IMNM that's a lot of buying at the end. Data must be coming soon.
0 · Reply
B00ger
B00ger Jul. 22 at 9:34 AM
$IMNM
0 · Reply
Jeff9905
Jeff9905 Jul. 20 at 5:14 PM
$IMNM all job openings taken down. Good or bad?
1 · Reply
StockBraker
StockBraker Jul. 17 at 4:40 PM
$IMNM Push it to 11
0 · Reply
Jeff9905
Jeff9905 Jul. 17 at 3:14 AM
$IMNM merck paid swtx 3.4 billion for their desmoid tumors treatment. Imnm lost again.
1 · Reply
Jeff9905
Jeff9905 Jul. 16 at 11:28 PM
$IMNM why is SWTX ahead of this on desmoid tumors?
1 · Reply
noseasmamon
noseasmamon Jul. 16 at 7:22 PM
$IMNM I'm liking this play
0 · Reply
Fast_Eddie_Felson
Fast_Eddie_Felson Jul. 16 at 7:19 PM
$IMNM offering? Only thing they have accomplished so far
1 · Reply
Elliotwavedave
Elliotwavedave Jul. 16 at 2:07 PM
$IMNM let’s go
0 · Reply
StockBraker
StockBraker Jul. 16 at 2:01 PM
$IMNM Infinity % increase is a new all time high for me. 🤑😂
0 · Reply
wwmeinc
wwmeinc Jul. 15 at 12:28 PM
$IOVA ... I take it you meant $IMNM ....easy to get them all mixed up...still they are a ~$750M Mkt Cap...."There is a Roche separation agreement on the 'net, detailing her(Roche) separation with Immunome Inc. back on Dec/23...effective...Jan/24"....legalize paperwork et al....she was hired on Mar/21.....had a 3 yr stint...well qualified no matter....just some 'net surfing this am....Did we actually get a GS downgrade??? Thanks. glta
1 · Reply